Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib

Akiko Nakano; Hirotsugu Ohkubo; Kensuke Fukumitsu; Satoshi Fukuda; Yoshihiro Kanemitsu; Masaya Takemura; Ken Maeno; Yutaka Ito; Tetsuya Oguri; Akio Niimi

doi:10.2169/internalmedicine.1890-18

This article has now been updated. Please use the final version.

Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib

Akiko Nakano, Hirotsugu Ohkubo, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Masaya Takemura, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Akio Niimi

Author information

Akiko Nakano
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Hirotsugu Ohkubo
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Kensuke Fukumitsu
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Satoshi Fukuda
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Yoshihiro Kanemitsu
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Masaya Takemura
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Ken Maeno
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Yutaka Ito
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Tetsuya Oguri
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Akio Niimi
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan

Keywords: Nintedanib, Idiopathic pulmonary fibrosis, KL-6, High-resolution computed tomography

JOURNAL OPEN ACCESS Advance online publication

Article ID: 1890-18

DOI https://doi.org/10.2169/internalmedicine.1890-18

The final version of this article is now available: Vol. 58 (2019), No. 8 pp. 1141-1144

Details

Abstract

Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. A 71-year-old man developed exertional dyspnea and was diagnosed with IPF. Four months after treatment with nintedanib, high-resolution computed tomography findings revealed reduced areas of ground-glass opacity and consolidation; 13 months after treatment, the FVC showed improvement from 3.07 to 3.43 L, and the serum KL-6 concentration showed a decline to normal levels. We herein report a patient with IPF who was considered a super responder to nintedanib.

Corresponding author

Register with J-STAGE for free!